Government of India will partner with Coalition for Epidemic Preparedness Innovations (CEPI) and pharma company Panacea Biotec, for developing a new Covid Vaccine.

Highlights

• They will develop vaccine candidates to provide broad protection against SARS-COV-2 variants as well as other beta coronaviruses.
• CEPI will be partnering with a consortium comprising of Translational Health Science and Technology Institute (THSTI) which is an autonomous institute of Department of Biotechnology under Ministry of Science and Technology and Panacea Biotec.

Development of Multi-epitope

• CEPI will provide funding of up to USD 12 million for supporting the development of multi-epitope, advance manufacturing process and nanoparticle-based vaccine candidates.
• For this, lead antigen will be designed and selected through proof-of-concept preclinical studies. Following this, CEPI will undertake initial clinical development through Phase 1 or 2 of studies.

Coalition for Epidemic Preparedness Innovations (CEPI)

CEPI is a foundation, taking donations from public, private, civil society organisations and philanthropic organisations for financing independent research projects in a bid to develop vaccines against emerging infectious diseases (EID). It focuses on “blueprint priority diseases” of World Health Organization. CEPI was conceived in 2015. But it was formally launched in 2017 at World Economic Forum (WEF) in Davos, Switzerland.